Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
PURPOSE: Non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor ( EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors. Amivantamab, an EGFR-MET bispecific antibody with immune cell–directing activity, binds to each receptor's extracellular domain, bypassing resistance at the tyrosine kinase inhibitor binding site. METHODS: CHRYSALIS is a phase I, open-label, dose-escalation, and dose-expansion study, which included a population with EGFR Exon20ins NSCLC. The primary end points were dose-limiting toxicity and overall response rate. We report findings from the postplatinum EGFR Exon20ins NSCLC population treated at the recommended phase II dose of 1,050 mg amivantamab (1,400 mg, ≥ 80 kg) given once weekly for the first 4 weeks and then once every 2 weeks starting at week 5. RESULTS: In the efficacy population (n = 81), the median age was 62 years (range, 42-84 years); 40 patients (49%) were Asian, and the median number of previous lines of therapy was two (range, 1-7). The overall response rate was 40% (95% CI, 29 to 51), including three complete responses, with a median duration of response of 11.1 months (95% CI, 6.9 to not reached). The median progression-free survival was 8.3 months (95% CI, 6.5 to 10.9). In the safety population (n = 114), the most common adverse events were rash in 98 patients (86%), infusion-related reactions in 75 (66%), and paronychia in 51 (45%). The most common grade 3-4 adverse events were hypokalemia in six patients (5%) and rash, pulmonary embolism, diarrhea, and neutropenia in four (4%) each. Treatment-related dose reductions and discontinuations were reported in 13% and 4% of patients, respectively. CONCLUSION: Amivantamab, via its novel mechanism of action, yielded robust and durable responses with tolerable safety in patients with EGFR Exon20ins mutations after progression on platinum-based chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · cited 9×
“Median previous lines of therapy (range) 3 (0-10) 2 (1-7)”
BackgroundInfluentialSelf-citationPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913662 · Cited by 2,914 · cited 6×
“Dry skin 18 (16) 18 (16) 0 0 33 (13) 32 (12) 1 (0.”
BackgroundSelf-citationHanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309 · cited 3×
“Paronychia 51 (45) 28 (25) 22 (19) 1 (1) 104 (40) 50 (19) 51 (20) 3 (1)”
BackgroundSelf-citationYang, J. C.-H., Sequist, L. V., Geater, S. L., Tsai, C.-M., Mok, T. S. K., Schuler, M., Yamamoto, N., Yu, C.-J., Ou, S.-H. I., Zhou, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00026-1 · Cited by 1,002 · cited 5×
“Increased alanine aminotransferase 17 (15) 15 (13) 1 (1) 1 (1) 30 (12) 22 (9) 5 (2) 3 (1)”
BackgroundInfluentialSelf-citationYasuda, H., Park, E., Yun, C.-H., Sng, N. J., Lucena-Araujo, A. R., Yeo, W.-L., Huberman, M. S., Cohen, D. W., Nakayama, S., Ishioka, K., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007205 · Cited by 571 · cited 8×
“Hypoalbuminemia 31 (27) 6 (5) 22 (19) 3 (3) 63 (24) 21 (8) 38 (15) 4 (2)”
BackgroundInfluentialArcila, M. E., Nafa, K., Chaft, J. E., Rekhtman, N., Lau, C., Reva, B. A., Zakowski, M. F., Kris, M. G., & Ladanyi, M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0620 · Cited by 473 · cited 9×
“Median previous lines of therapy (range) 3 (0-10) 2 (1-7)”
BackgroundInfluentialRobichaux, J. P., Elamin, Y. Y., Tan, Z., Carter, B. W., Zhang, S., Liu, S., Li, S., Chen, T., Poteete, A., Estrada-Bernal, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0007-9 · Cited by 468 · cited 4×
“Decreased appetite 16 (14) 7 (6) 9 (8) 0 39 (15) 23 (9) 16 (6) 0”
BackgroundInfluentialNatural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions
Oxnard, G. R., Lo, P. C., Nishino, M., Dahlberg, S. E., Lindeman, N. I., Butaney, M., Jackman, D. M., Johnson, B. E., & Jänne, P. A. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182779d18 · Cited by 360 · cited 7×
“Median previous lines of therapy (range) 3 (0-10) 2 (1-7)”
BackgroundInfluentialBeau-Faller, M., Prim, N., Ruppert, A.-M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., Escande, F., Lizard, S., Pretet, J.-L., Rouquette, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt418 · Cited by 324 · cited 3×
“Median time from initial diagnosis, months (range) 37 (2-173) 17 (1-130)”
BackgroundStructure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer
Kumar, A., Petri, E. T., Halmos, B., & Boggon, T. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1178 · Cited by 308
Yun, J., Lee, S.-H., Kim, S.-Y., Jeong, S.-Y., Kim, J.-H., Pyo, K.-H., Park, C.-W., Heo, S. G., Yun, M. R., Lim, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0116 · Cited by 297 · cited 2×
“Median time from initial diagnosis, months (range) 37 (2-173) 17 (1-130)”
BackgroundSelf-citationMoores, S. L., Chiu, M. L., Bushey, B. S., Chevalier, K., Luistro, L., Dorn, K., Brezski, R. J., Haytko, P., Kelly, T., Wu, S.-J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2833 · Cited by 286
Lee, C. K., Davies, L., Wu, Y.-L., Mitsudomi, T., Inoue, A., Rosell, R., Zhou, C., Nakagawa, K., Thongprasert, S., Fukuoka, M., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djw279 · Cited by 252
Self-citationRiess, J. W., Gandara, D. R., Frampton, G. M., Madison, R., Peled, N., Bufill, J. A., Dy, G. K., Ou, S.-H. I., Stephens, P. J., McPherson, J. D., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.06.019 · Cited by 240 · cited 6×
“Median previous lines of therapy (range) 3 (0-10) 2 (1-7)”
BackgroundInfluentialNaidoo, J., Sima, C. S., Rodriguez, K., Busby, N., Nafa, K., Ladanyi, M., Riely, G. J., Kris, M. G., Arcila, M. E., & Yu, H. A. (2015) · Cancer · doi:10.1002/cncr.29493 · Cited by 211 · cited 3×
“Fatigue 21 (18) 15 (13) 4 (4) 2 (2) 47 (18) 29 (11) 16 (6) 2 (1)”
BackgroundVijayaraghavan, S., Lipfert, L., Chevalier, K., Bushey, B. S., Henley, B., Lenhart, R., Sendecki, J., Beqiri, M., Millar, H. J., Packman, K., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0071 · Cited by 206
Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy
Huang, S., van Duijnhoven, S. M. J., Sijts, A. J. A. M., & van Elsas, A. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03404-6 · Cited by 127
Le, X., Goldman, J. W., Clarke, J. M., Tchekmedyian, N., Piotrowska, Z., Chu, D. T. W., Bhat, G., Lebel, F. M., & Socinski, M. A. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9514 · Cited by 100
Haura, E. B., Cho, B. C., Lee, J. S., Han, J.-Y., Lee, K. H., Sanborn, R. E., Govindan, R., Cho, E. K., Kim, S.-W., Reckamp, K. L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.9009 · Cited by 96
Self-citationPark, K., John, T., Kim, S.-W., Lee, J. S., Shu, C. A., Kim, D.-W., Viteri Ramirez, S., Spira, A. I., Sabari, J. K., Han, J.-Y., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9512 · Cited by 67
Self-citationWu, J., Yu, C., & Shih, J. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.06.018 · Cited by 63
Jarantow, S. W., Bushey, B. S., Pardinas, J. R., Boakye, K., Lacy, E. R., Sanders, R., Sepulveda, M. A., Moores, S. L., & Chiu, M. L. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.651653 · Cited by 61
Kate, S., Chougule, A., Joshi, A., Noronha, V., Patil, V., Dusane, R., Solanki, L., Tiwrekar, P., Trivedi, V., & Prabhash, K. (2019) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s181406 · Cited by 54
Cho, B. C., Lee, K. H., Cho, E. K., Kim, D.-W., Lee, J. S., Han, J.-Y., Kim, S.-W., Spira, A. I., Haura, E. B., Sabari, J. K., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.1572 · Cited by 39
Self-citationKim, T. M., Ock, C., Kim, M., Kim, S. H., Keam, B., Kim, Y. J., Kim, D.-W., Lee, J.-S., & Heo, D. S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz260.051 · Cited by 34
Self-citationZhou, C., Ramalingam, S. S., Li, B., Fang, J., Kim, T. M., Kim, S., Yang, J. C., Riely, G. J., Mekhail, T. M., Nguyen, D., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.283 · Cited by 32
Self-citationCho, B. C., Lee, J.-S., Han, J., Cho, E. K., Haura, E. B., Lee, K. H., Bauml, J. M., Sanborn, R. E., Curtis, M., Attiyeh, E. F., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy292.118 · Cited by 15
Self-citation
Cited by
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,392
Lung cancer immunotherapy: progress, pitfalls, and promises
Lahiri, A., Maji, A., Potdar, P. D., Singh, N., Parikh, P., Bisht, B., Mukherjee, A., & Paul, M. K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01740-y · Cited by 1,102
Non–Small Cell Lung Cancer, Version 4.2024
Riely, G. J., Wood, D. E., Ettinger, D. S., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2204.0023 · Cited by 855
Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.009 · Cited by 853
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Metadata
- Authors
- Park, K., Haura, E. B., Leighl, N. B., Mitchell, P., Shu, C. A., Girard, N., Viteri, S., Han, J.-Y., Kim, S.-W., Lee, C. K., Sabari, J. K., Spira, A. I., Yang, T.-Y., Kim, D.-W., Lee, K. H., Sanborn, R. E., Trigo, J., Goto, K., Lee, J.-S., Yang, J. C.-H., Govindan, R., Bauml, J. M., Garrido, P., Krebs, M. G., Reckamp, K. L., Xie, J., Curtin, J. C., Haddish-Berhane, N., Roshak, A., Millington, D., Lorenzini, P., Thayu, M., Knoblauch, R. E., & Cho, B. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2021-10-20
- Volume
- 39
- Issue
- 30
- Pages
- 3391-3402
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3191219220
- Cited by
- 655
- References
- 31
- FWCI
- 64.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.